Discovery - University of Dundee - Online Publications

Library & Learning Centre

The evidence for antiresorptive osteoporosis treatment in the elderly and old

Standard

The evidence for antiresorptive osteoporosis treatment in the elderly and old. / Maraldo, M. V.; Vestergaard, P.; McMurdo, M. E. T.; Schwarz, P.

In: European Geriatric Medicine, Vol. 1, No. 5, 10.2010, p. 279-292.

Research output: Contribution to journalArticle

Harvard

Maraldo, MV, Vestergaard, P, McMurdo, MET & Schwarz, P 2010, 'The evidence for antiresorptive osteoporosis treatment in the elderly and old' European Geriatric Medicine, vol 1, no. 5, pp. 279-292., 10.1016/j.eurger.2010.08.002

APA

Maraldo, M. V., Vestergaard, P., McMurdo, M. E. T., & Schwarz, P. (2010). The evidence for antiresorptive osteoporosis treatment in the elderly and old. European Geriatric Medicine, 1(5), 279-292. 10.1016/j.eurger.2010.08.002

Vancouver

Maraldo MV, Vestergaard P, McMurdo MET, Schwarz P. The evidence for antiresorptive osteoporosis treatment in the elderly and old. European Geriatric Medicine. 2010 Oct;1(5):279-292. Available from: 10.1016/j.eurger.2010.08.002

Author

Maraldo, M. V.; Vestergaard, P.; McMurdo, M. E. T.; Schwarz, P. / The evidence for antiresorptive osteoporosis treatment in the elderly and old.

In: European Geriatric Medicine, Vol. 1, No. 5, 10.2010, p. 279-292.

Research output: Contribution to journalArticle

Bibtex - Download

@article{94d547039bfc406e9f3778bfb7ecd388,
title = "The evidence for antiresorptive osteoporosis treatment in the elderly and old",
keywords = "Hip fracture risk, Non-vertebral fracture risk, Old, Osteoporosis, Vertebral fracture risk, FRACTURE INTERVENTION TRIAL, HORMONE REPLACEMENT THERAPY, SPRAY SALMON-CALCITONIN, BONE-MINERAL DENSITY, POSTMENOPAUSAL OSTEOPOROSIS, STRONTIUM RANELATE, NONVERTEBRAL FRACTURES, RANDOMIZED-TRIAL, VERTEBRAL FRACTURES, PREVENTING OSTEOPOROSIS",
author = "Maraldo, {M. V.} and P. Vestergaard and McMurdo, {M. E. T.} and P. Schwarz",
year = "2010",
doi = "10.1016/j.eurger.2010.08.002",
volume = "1",
number = "5",
pages = "279--292",
journal = "European Geriatric Medicine",
issn = "1878-7649",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - The evidence for antiresorptive osteoporosis treatment in the elderly and old

A1 - Maraldo,M. V.

A1 - Vestergaard,P.

A1 - McMurdo,M. E. T.

A1 - Schwarz,P.

AU - Maraldo,M. V.

AU - Vestergaard,P.

AU - McMurdo,M. E. T.

AU - Schwarz,P.

PY - 2010/10

Y1 - 2010/10

N2 - <p>Purpose. - The mean age at diagnosis of osteoporosis is in the late 1960s, and fracture risk and need for fracture prevention rises sharply with increasing age. However, what is the evidence that supports the use of antiresorptive osteoporosis treatments in elderly people?</p><p>Methods. - This study was a meta-analysis and meta-regression of the published literature on the clinical efficacy of antiresorptive therapy in the reduction of fracture risk in elderly (age &gt; 70 years) and old (age &gt; 80 years). A systematic literature search was performed. Studies included were randomised placebo controlled trials of post-menopausal women or men where the primary endpoint was vertebral, non-vertebral or hip fracture risk reduction. No papers on fractures in males were published, so BMD as primary endpoint was accepted.</p><p>Results. - Thirteen studies in women were included. We found increasing vertebral fracture risk reduction with increasing age, increasing BMI, and longer duration of treatment. A high baseline BMD was associated with a lesser effect. For non-vertebral fracture risk reduction, we found no effect of follow-up, age or BMD. For hip fracture risk reduction, we found no effect of treatment with increasing age or BMD, and no certain effect of duration of treatment. For men, three BMD studies were included, in these, we found a non-significant trend toward fracture reduction.</p><p>Conclusions. - For women, pooled analyses showed increasing effect of antiresorptive drugs with increasing age, increasing BMI, and longer duration of treatment on vertebral fractures. The data on non-vertebral or hip fractures showed no effect on follow-up, age, or BMD. The data in men are scant at all sites and inconclusive. (C) 2010 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.</p>

AB - <p>Purpose. - The mean age at diagnosis of osteoporosis is in the late 1960s, and fracture risk and need for fracture prevention rises sharply with increasing age. However, what is the evidence that supports the use of antiresorptive osteoporosis treatments in elderly people?</p><p>Methods. - This study was a meta-analysis and meta-regression of the published literature on the clinical efficacy of antiresorptive therapy in the reduction of fracture risk in elderly (age &gt; 70 years) and old (age &gt; 80 years). A systematic literature search was performed. Studies included were randomised placebo controlled trials of post-menopausal women or men where the primary endpoint was vertebral, non-vertebral or hip fracture risk reduction. No papers on fractures in males were published, so BMD as primary endpoint was accepted.</p><p>Results. - Thirteen studies in women were included. We found increasing vertebral fracture risk reduction with increasing age, increasing BMI, and longer duration of treatment. A high baseline BMD was associated with a lesser effect. For non-vertebral fracture risk reduction, we found no effect of follow-up, age or BMD. For hip fracture risk reduction, we found no effect of treatment with increasing age or BMD, and no certain effect of duration of treatment. For men, three BMD studies were included, in these, we found a non-significant trend toward fracture reduction.</p><p>Conclusions. - For women, pooled analyses showed increasing effect of antiresorptive drugs with increasing age, increasing BMI, and longer duration of treatment on vertebral fractures. The data on non-vertebral or hip fractures showed no effect on follow-up, age, or BMD. The data in men are scant at all sites and inconclusive. (C) 2010 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.</p>

KW - Hip fracture risk

KW - Non-vertebral fracture risk

KW - Old

KW - Osteoporosis

KW - Vertebral fracture risk

KW - FRACTURE INTERVENTION TRIAL

KW - HORMONE REPLACEMENT THERAPY

KW - SPRAY SALMON-CALCITONIN

KW - BONE-MINERAL DENSITY

KW - POSTMENOPAUSAL OSTEOPOROSIS

KW - STRONTIUM RANELATE

KW - NONVERTEBRAL FRACTURES

KW - RANDOMIZED-TRIAL

KW - VERTEBRAL FRACTURES

KW - PREVENTING OSTEOPOROSIS

U2 - 10.1016/j.eurger.2010.08.002

DO - 10.1016/j.eurger.2010.08.002

M1 - Article

JO - European Geriatric Medicine

JF - European Geriatric Medicine

SN - 1878-7649

IS - 5

VL - 1

SP - 279

EP - 292

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy